Maribavir for treatment of cytomegalovirus infection in a liver-transplanted patient.
Ugeskr Laeger
; 186(15)2024 Apr 08.
Article
in Da
| MEDLINE
| ID: mdl-38708697
ABSTRACT
Cytomegalovirus infection (CMV) can be fatal for organ transplant recipients as shown in this case report. Maribavir is a recently approved drug, which can be used for therapy-refractory CMV infection or when other treatment options cannot be used. The patient in this case report was a CMV-infected liver transplant recipient, who developed a severe erythema and high CMV DNA during valganciclovir therapy. Toxic epidermal necrolysis was suspected. The patient was treated with maribavir, and both CMV DNA and the skin normalised. This case illustrates that maribavir is a useful alternative to other antiviral drugs for CMV infection.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Antiviral Agents
/
Ribonucleosides
/
Liver Transplantation
/
Cytomegalovirus Infections
/
Dichlororibofuranosylbenzimidazole
Limits:
Humans
/
Male
/
Middle aged
Language:
Da
Journal:
Ugeskr Laeger
Year:
2024
Document type:
Article